Subsequent renal biopsies are not usually recommended for follow-up in patients after AHSCT.
To test this hypothesis would require more frequent testing for monoclonal proteins after AHSCT for AL amyloid.
Typically, patients are evaluated and screened for free light chains monthly after AHSCT, then every 3 months, if they are clinically stable or improving.
Age is less of a barrier to AHSCT than allogeneic transplantation because of the absence of graft-vs-host disease.
Specffic Diseases in Which AHSCT Has Been Evaluated
In this section, we summarize currently available data relating to the efficacy of AHSCT in certain of the more commonly applied disease settings.
Randomized comparative data in first complete remission (CR) studies as well as studies in which high-dose consolidation control arms without AHSCT were used have recently been completed and communicated.
A 23-year-old female acute myeloblastic leukemia (ALL) patient underwent AHSCT from an HLA fully matched cousin during her second complete remission in March 2009.
A 26-year-old male ALL patient underwent AHSCT from an unrelated donor during his second complete remission in July 2009.
A 35-year-old male patient underwent AHSCT from an HLA fully matched sibling in November 2008, following autologous transplantation due to refractory Hodgkin's disease.
In this study, we describe the clinical features of 22 patients with sclerodermatous cGVHD who had received AHSCT.
The length of time between AHSCT and the onset of sclerodermatous cGVHD has been reported within a wide range (292-2190 days, mean 730) (1-3), (5).